AMAG Pharmaceuticals Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AP</div>
AMAG -- USA Stock  

USD 13.75  0.00  0.00%

As many rational traders are trying to avoid healthcare space, it makes sense to digest AMAG Pharmaceuticals a little further and understand how it stands against NantKwest and other similar entities. We are going to discuss some of the competitive aspects of both AMAG Pharmaceuticals and NantKwest.
Published over three weeks ago
View all stories for AMAG Pharmaceuticals | View All Stories
What is our outlook on AMAG Pharmaceuticals (NASDAQ:AMAG) and NantKwest (NASDAQ:NK)?
By analyzing existing basic indicators between AMAG Pharmaceuticals and NantKwest, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in NantKwest with a short position in AMAG Pharmaceuticals. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AMAG Pharmaceuticals has an asset utilization ratio of 12.02 percent. This indicates that the company is making $0.12 for each dollar of assets. An increasing asset utilization means that AMAG Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as AMAG Pharmaceuticals or WXIBF is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is AMAG Pharmaceuticals's Liquidity

AMAG Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance AMAG Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. AMAG Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between AMAG Pharmaceuticals's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for AMAG Pharmaceuticals, but it might be worth checking our own buy vs. sell analysis

Correlation Between AMAG Pharmaceuticals and WUXI BIOLOGICS INC

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding AMAG Pharmaceuticals together with similar or unrelated positions with a negative correlation. For example, you can also add WUXI BIOLOGICS to your portfolio. If WUXI BIOLOGICS is not perfectly correlated to AMAG Pharmaceuticals it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When AMAG Pharmaceuticals for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between AMAG and WXIBF for more information.

Note

Are you currently holding both AMAG Pharmaceuticals and WUXI BIOLOGICS in your portfolio? Please note if you are using this as a pair-trade strategy between AMAG Pharmaceuticals and WUXI BIOLOGICS, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses.

Breaking down AMAG Pharmaceuticals Indicators

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me now analyze AMAG Pharmaceuticals revenue. Based on the latest financial disclosure, AMAG Pharmaceuticals reported 297.7 M of revenue. This is 96.1% lower than that of the Healthcare sector and 59.93% lower than that of the Biotechnology industry. The revenue for all United States stocks is 96.84% higher than that of AMAG Pharmaceuticals. As for NantKwest we see revenue of 43 K, which is 99.99% lower than that of the Biotechnology

AMAG Pharmaceuticals297.7 Million
Sector742.91 Million
NantKwest43,000
297.7 M
AMAG Pharmaceuticals
742.9 M
Sector
NantKwest

AMAG Pharmaceuticals is projected to stay under $13.98 in December

Downside variance is down to 12.65. It may indicate a possible volatility dip. As of the 1st of November, AMAG Pharmaceuticals owns the coefficient of variation of 950.56, and Market Risk Adjusted Performance of (14.42). AMAG Pharmaceuticals technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to analyze nineteen technical drivers for AMAG Pharmaceuticals, which can be compared to its peers in the sector. Please confirm AMAG Pharmaceuticals jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if AMAG Pharmaceuticals is priced correctly, providing market reflects its prevailing price of 13.71 per share. Given that AMAG Pharmaceuticals has jensen alpha of 0.6513, we suggest you to validate AMAG Pharmaceuticals's latest market performance to make sure the company can sustain itself in the future.

Our Final Take On AMAG Pharmaceuticals

Although other companies within the biotechnology industry are still a little expensive, even after the recent corrections, AMAG Pharmaceuticals may offer a potential longer-term growth to shareholders. While some shareholders may not share our view, we believe that right now is not a good time to increase your holdings in AMAG Pharmaceuticals. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to AMAG Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of AMAG Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com